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Prostate-specific antigen (PSA), a 33kDa glycoprotein, is
regarded as a reliable surrogate marker for survival and disease
progression in patients with androgen-independent prostate cancer
(AIPC) (Sridhara et al, 1995). Approximately 90% of patients with
advanced metastatic prostate cancer have an elevated PSA (Figg et
al, 1996). Furthermore, by multivariant analysis, PSA level is a
predictor of clinical outcome. Kelly and colleagues found a
median survival of > 25 months in those patients exhibiting a
greater than 50% decline in PSA following an investigational
regimen versus 8.6 months in those patients not achieving that
level (Kelly et al, 1993). Our group reported a median survival of
19.0 versus 6.3 months in patients with AIPC that experienced a
50% PSA decline versus those that did not (Thibault et al, 1993).
Concern has been raised that some investigational agents may
affect PSA production or secretion without altering tumour growth
or volume. Phenylacetate, a-interferon and cis-retinoic acid have
been shown to up-regulate PSA expression (Walls et al, 1996).
These are differentiation agents and may effect PSA through that
mechanism. However, carboxy-amidotriazole, an antimetastatic,
antiproliferative agent, has been reported to down-regulate PSA
expression (Wasilenko et al, 1996). Suramin also has been
reported to inhibit PSA expression (Thalmann et al, 1996). Thus,
the utilization of PSA as a surrogate marker is questionable
without first evaluating the effect of new investigational drugs on
PSA production.
Proliferation of new blood vessels is essential to continued
growth of solid tumours and inhibition of angiogenesis has been
proposed as a potential means for selectively impairing tumour
growth (Folkman and Ingber, 1992). Compounds that inhibit
angiogenesis include protamine (Taylor and Folkman, 1982),
interferon (Voest et al, 1995), specific steroids in combination with
heparin (Thorpe et al, 1993), a sulfated polysaccharide–peptido-
glycan complex (Inuoe et al, 1988), pentosan (Lush et al, 1996),
thalidomide (Figg et al, 1997a), platelet factor-4 (Maione et al,
1990) and D-penicillamine (Matsubara et al, 1989). A new class of
compounds was discovered when a fungal contaminant of a capil-
lary endothelial cell culture was observed to produce a zone of
endothelial cell rounding, a phenomenon characteristic of other
antiangiogenic compounds (Ingber et al, 1990). The substance
responsible for this phenomenon was fumagillin, an antibiotic
naturally secreted by the fungus Aspergillus fumigatus. Although
fumagillin had anti-angiogenic activity both in endothelial cell
cultures and in vivo, it caused severe weight loss in mice with
prolonged administration. A search to identify less toxic analogues
yielded TNP-470 which was 50 times more potent than fumagillin
in inhibiting capillary growth and was less toxic.
One possible mechanism for the effect of TNP-470 on angio-
genesis is inhibition of growth factor-induced DNA synthesis in
endothelial cells. TNP-470 potently inhibits endothelial cell growth
and cytotoxicity occurs at concentrations greater than 1mg ml–1
(Kusaka et al, 1991; Kato et al, 1994). The angioinhibitory activity
appears to involve transcriptional inhibition of specific cdk and
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cyclin gene family members. TNP-470 may also inhibit cdc2 and
cdk2 kinase activation in endothelial cells (Kato et al, 1994).
Alteration of thrombospondin production, an important regulator of
endothelial cell proliferation and angiogenesis, is another proposed
mechanism of action (Abe et al, 1994; Kato et al, 1994).
Kusaka and associates demonstrated inhibition of in vitro capil-
lary growth and induction of avascular zones in the chick chorioal-
lantoic membrane assay (Kusaka et al, 1991). A rat corneal
micropocket assay showed 20 mg TNP-470 per cornea suppressed
the number and length of blood vessels induced by basic fibroblast
growth factor (bFGF). In the sponge implantation model in rats,
systemic administration of TNP-470 inhibited angiogenesis induced
by bFGF. Finally, in the rat blood vessel organ culture assay, 1 ng
ml–1 TNP-470 inhibited capillary-like tube formation (Kusaka et al,
1991; Bauer et al, 1998). TNP-470 also inhibited solid tumour
growth in animal models (Ingber et al, 1990; Kusaka et al, 1991;
Kato et al, 1994; O’Reilly et al, 1995). Ingber and colleagues
reported that 30 mg kg–1 TNP-470 every other day inhibited the
growth of Lewis lung carcinoma, B16 melanoma, and other mouse
tumours (Ingber et al, 1990). In some studies, tumour inhibition was
noted with administration as infrequently as once a week. The dose-
limiting toxicity of TNP-470 in dogs was cerebral bleeding when
high doses were given as a bolus (Masiero et al, 1997).
Logothetis et al have completed a phase I study of TNP-470 in
patients with AIPC (Logothetis et al, 1997). They reported a
maximum tolerated dose of 70.88 mg m–2 when a 1 h intravenous
infusion was administered every other day for 28 days, repeated
every 6 weeks. In this trial, several patients had serum PSA eleva-
tions while receiving active therapy that reversed upon discontinu-
ation. Sartor reported a TNP-470 withdrawal phenomenon in a
single patient with metastatic prostate cancer (Sartor, 1995). Based
on these observations, we wanted to determine if TNP-470, or its
metabolite, AGM-1883, alters PSA secretion in an in vitro system.
Furthermore, we wanted to determine if protein expression or
transcription was altered in LNCaP cells exposed to clinically
achievable concentrations of either of these compounds.
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Figure 1 The number of LNCaP cells determined every 24 h following initial
exposure to three concentrations of either (A) TNP-470 or (B) AGM-1883.
Each result is the mean of the cell counts obtained from three wells (±SD).
The (l) represent control wells; (n) were treated at 50 ng ml–1; (u) were
treated at 500 ng ml–1; and (s) were treated at 1000 ng ml–1
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Figure 2 The amount of PSA (fg) normalized to the cell number every 24 h
following an initial exposure to either (A) TNP-470 or (B) AGM-1883. Each
value represents the mean of the PSA values measured for each well divided
by the corresponding cell number (± SD) normalized to control1590 J Horti et al
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MATERIALS AND METHODS
Cell culture
The human androgen-dependent prostate carcinoma cell line,
LNCaP, was obtained from the American Type Culture Collection
(Manassas, VA, USA) and grown as directed. Cells, passage 25,
were plated at 30 000 cells per 2-cm well. TNP-470 and AGM-
1883 were gifts from the Takeda Pharmaceutical Ltd (Oseka,
Japan) and prepared as stock solutions in dimethyl sulfoxide
(DMSO). Serial dilutions were prepared in culture medium to
produce final concentrations of 50, 500 and 1000 ng ml–1. The
final DMSO concentration was 0.5%. Cells were treated daily.
PSA quantification
Every 24 h, the supernatants were collected. Adherent cells were
trypsinized and counted on a Coulter Z1 counter (Coulter
Electronics, Hialeah, FL, USA). PSA secreted into the supernatant
was measured using the Tandem-E PSA assay (Hybritech, San
Diego, CA, USA) according to the company’s instructions. The
amount of PSA secreted per cell was calculated for every 24 h period.
Immunoblots for PSA and AR
Following treatment for 120 h, adherent cells were collected by
trypsinization. The cells were washed with phosphate-buffered
saline and pelleted. Cytosolic protein was extracted by resus-
pending cells in 10 mM HEPES, pH 7.4, 1 mM EDTA and protease
inhibitors (completeØ, Boehringer-Mannheim, Indianapolis, IN,
USA) followed by three cycles of freezing and thawing. Cellular
debris was pelleted and the supernatant saved. The amount of
protein was determined using the BioRad protein assay (BioRad,
Hercules, CA, USA). Equal amounts of protein were separated on
polyacrylamide-SDS gels, then transferred to nitrocellulose. Blots
were developed according to Western-Light chemiluminescent
detection system (Tropix, Bedford, MA, USA) using a mouse anti-
PSA (Cappel, Aurora, OH, USA) or a mouse anti-human androgen
receptor (AR) antibody (Pharmingen, San Diego, CA, USA). The
secondary antibody was alkaline phosphatase-conjugated goat
anti-mouse IgG (Promega, Madison, WI, USA).
Reverse transcriptase-polymerase chain reaction assay
LNCaP cells, passage 26, were plated at a density of 45 000 cells
per 2-cm well. After 48 h, the cells were treated with 50 ng ml–1
TNP-470. At each time-point, the supernatant was aspirated and
the adherent cells lysed in TriZol (Life Technologies,
Gaithersburg, MD, USA). Total RNA was extracted according to
the manufacturer’s protocol. Contaminating genomic DNA was
digested with DNAse I (Ambion, Austin, TX, USA) and first
strand cDNA was prepared using an oligo(dT) primer and
SuperscriptTM II reverse transcriptase (Life Technologies,
Gaithersburg, MD, USA). Each cDNA:RNA hybrid was digested
with RNase H. The final cDNA product was diluted threefold in 
10 mM Tris-HCl, pH 7.4, 1 mM EDTA.
PSA and AR primers were synthesized by BioServe
Biotechnologies (Laurel, MD, USA) and are as follows: PSA 614,
5¢-ATGAGCCTCCTGAAGAATCGATTCCTC-3¢; PSA 1154,
5¢-AGTCTTGGCCTGGTCATTTCCAAGGT-3¢; AR 2381, 5¢-
TGGGGCTCATGGTGTTTG-3¢; and AR 2881, 5¢-CAGAAAG-
GATCTTGGGCAC-3¢. Primers are numbered to correspond to the
base in the published sequence to where the primers anneal. HMR
GAPDH polymerase chain reaction (PCR) primers were purchased
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Figure 3 Immunoblots detecting PSA and AR in LNCaP cell extracts
treated with TNP-470 or AGM-1883 at 50, 500 and 1000 ng ml–1. There was
an increase in PSA production with both agents following exposure for 120 h.
In contrast, AR shows a slight down-regulation which may be indicative of
destabilization of the receptor
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Figure 4 PCR amplification of cDNA isolated from LNCaP cells treated with
50 ng ml–1 TNP-470. Each cDNA was amplified in duplicate for (A) PSA, 
540 bp; (B) AR, 500 bp; or (C) GAPDH, 454 bp. Equivalent volumes of each
PCR product was loadedTNP-470 affects prostate-specific antigen 1591
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from Clontech (Palo Alto, CA, USA). For each pair of primers, the
sequence to be amplified was subcloned into pCR-Script™ AMP
SK(+) (Stratagene, San Diego, CA, USA) to serve as a positive
control. PCR was performed on 2 ng of positive control or 1 ml
diluted cDNA in the presence of 50 mM Tris-HCl, pH 8.3, 
250 mg ml–1 bovine serum albumin, 2 mM magnesium chloride for
AR or 3 mM magnesium chloride for PSA and GAPDH, 0.5%
Ficoll 400, 1 mM tartrazine, 500 mM of each dNTP, 1 mM of each
primer, and 0.5 U AmpliTaq (Perkin-Elmer, Foster City, CA, USA)
in a volume of 10 ml. Thermal cycling parameters for each primer
set were optimized fall within a linear amplification range. The
thermal cycling programme consisted of denaturation at 94°C for
15 s followed by several cycles of denaturation at 94°C for 0 s,
annealing at the optimized temperature for 0 s, and extension at
72°C for 30 s. The cycle number and annealing temperature for the
three primer sets were: 27 cycles and 60°C for PSA; 29 cycles and
55°C for AR; and 22 cycles and 50°C for GAPDH. PCR products
(7 ml) were separated on agarose gels. The gels were stained with
SYBR Green I (Molecular Probes, Eugene, OR, USA) and scanned
on a Fluorimager SI (Molecular Dynamics, Sunnyvale, CA, USA).
Bands were quantitated using NIH Image 1.6. Differences in RNA
isolation and cDNA synthesis efficiencies between time-points and
duplicates were accounted for by normalization of each band to the
level of GAPDH detected at the same time-point. Induction was
determined relative to the initial time-point.
RESULTS
After 120 h, TNP-470 treatment resulted in a 40.6% decrease in cell
number at the highest concentration (Figure 1A). The mean number
of cells per well was 3.82 ´104at 50 ng ml, 4.47 ´104at 500 ng ml–1,
and 4.65 ´ 104 at 1000 ng ml–1 TNP-470. The mean cell number in
control wells was 7.83 ´ 104. AGM-1883 had a minimal effect on
cell viability resulting in a 16.6% decrease in cell number at 
the highest concentration (Figure 1B). After 120 h, there were 3.84 ´
104, 4.74 ´ 104, and 3.47 ´ 104 cells/well at 50, 500, and 1000 ng
ml–1, respectively, compared to 4.16 ´ 104 cells/well for controls.
TNP-470 treatment resulted in a 1.1- to 1.5-fold induction in
PSA secretion per cell that was concentration-dependent (Figure
2A). Lower concentrations of TNP-470 up-regulated PSA secre-
tion per cell better than higher concentrations. The concentration
of PSA in the supernatant at 120 h was 2616.5 fg/cell at 50 ng
ml–1, 2055.9 fg/cell at 500 ng ml–1, 1921.5 fg/cell at 1000 ng ml–1
versus 1716.6 fg/cell for the controls. The same trends were
observed for AGM-1883 with the amount of PSA secreted per cell
up-regulated approximately 30–70% compared to controls (Figure
2B). However, no concentration-dependency was observed in
response to AGM-1883. Immunoblots of cell extracts treated with
TNP-470 or AGM-1883 for 120 h showed equivalent increases in
intracellular PSA (Figure 3). The AR, on the other hand, shows a
slight down-regulation in intracellular protein levels relative to
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Figure 5 A patient with Stage D2 AIPC who received two cycles of TNP-470 (over 4 weeks separated by a 2-week break) had a rise in his PSA while
receiving therapy. His PSA declined with the discontinuation of treatment and rose slowly after being removed from study1592 J Horti et al
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control (approximately 10% decrease). This decrease may be due
to instability of the AR protein in the presence of these agents.
The effect of TNP-470 on PSA and AR transcription was quan-
titated using RT-PCR. Both PSA and AR showed a transcriptional
up-regulation that peaked within 30 min of TNP-470 exposure
then declined to baseline levels by 9 h (Figure 4). PSA transcrip-
tion was increased 1.4-fold at 30 min, while AR transcription was
induced 1.2-fold. The increased transcriptional activity from the
PSA gene accounts for the increased amount of PSA secreted per
cell. Increased AR transcription was reflected by similar increases
at the protein level.
DISCUSSION
TNP-470, a semi-synthetic derivative of fumagillin, was discov-
ered by Ingber et al (1990) to inhibit capillary endothelial cell
growth. Figg et al (1994, 1997b) characterized the pharmaco-
kinetic profile of TNP-470 obtained as part of a dose escalation
phase I trial. There was a linear relationship between TNP-470
dose and AUC(inf) and between TNP-470 dose and peak plasma
concentrations (Cmax). The Cmax ranged from 6.6 ng ml–1 at the
lowest dose level to 597.1 ng ml–1 at the highest dose level. TNP-
470 was rapidly cleared from the circulation with a short terminal
half-life (0.88 ± 2.5 h) consistent with preclinical data. The Cmax
of AGM-1883, an active metabolite, ranged between 0.4 to 
158.1 ng ml–1. Concentrations of TNP-470 that yielded in vitro
activity were clinically achievable. In our in vitro experiments,
TNP-470 causes an initial decrease in LNCaP cell number at 48 h.
Subsequently, cell number was constant throughout the remainder
of the treatment period. Cytotoxicity was not noted. AGM-1883
also showed an initial decrease in cell number compared to the
control. However, the cell number continued to increase
throughout the treatment period, but with a slower doubling time
than untreated cells. Thus, it appears that TNP-470 has a slightly
stronger cytostatic activity than its metabolite.
Logothetis et al (1997) reported the maximum tolerated dose of
TNP-470 to be 70.8 mg m–2 and the dose-limiting toxicity as a
reversible neuropsychiatric symptom complex (asthenia, ataxia,
agitation). They were unable to document any anti-tumour activity
in their phase I study, but did note a transient stimulation of serum
PSA in a subset of patients. In fact, between 33% and 100% of
patients at each dose level had > 50% decline in PSA on two
consecutive measurements after cessation of therapy. A case report
of a single patient treated with TNP-470 illustrates the dilemma of
alterations in PSA independent of anti-tumoral activity may result
(Logothetis et al, 1997). In this instance, the patient had a rise in
his serum PSA concentration while receiving therapy, followed by
a decline in PSA with the discontinuation of TNP-470 (Figure 5).
The apparent dissociation between PSA levels and tumour
progression in this case and the experience reported by the MD
Anderson Cancer Center (unpublished) suggests that this
phenomena of PSA expression is reflected clinically.
Our data show that TNP-470 results in a moderate to substantial
increase in PSA secreted per cell that is concentration-dependent.
Equivalent increases in intracellular PSA were also detected. The
active metabolite, AGM-1883, also increased PSA production.
However, the increase in PSA secretion in response to AGM-1883
treatment was not concentration-dependent. The increased tran-
scription activity from the PSA gene accounts for the increased
amount of PSA produced and secreted by the cell. Increased AR
protein could also be accounted for by corresponding increases in
AR transcription. Thus, it appears that the mechanism of PSA up-
regulation by TNP-470 is at the transcriptional level. For individ-
uals with prostate cancer receiving TNP-470, these data suggest
that PSA is not a reliable surrogate marker.
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